Controlling graft-versus-host disease (GVHD) remains a major unmet need in stem cell transplantation, and new, targeted therapies are being actively developed. CD28-CD80/86 costimulation blockade represents a promising strategy, but targeting CD80/CD86 with CTLA4-Ig may be associated with undesired blockade of coinhibitory pathways. In contrast, targeted blockade of CD28 exclusively inhibits T cell costimulation and may more potently prevent GVHD. Here, we investigated FR104, an antagonistic CD28-specific pegylated-Fab′, in the nonhuman primate (NHP) GVHD model and completed a multiparameter interrogation comparing it with CTLA4-Ig, with and without sirolimus, including clinical, histopathologic, flow cytometric, and transcriptomic analyses. We document that FR104 monoprophylaxis and combined prophylaxis with FR104/sirolimus led to enhanced control of effector T cell proliferation and activation compared with the use of CTLA4-Ig or CTLA4-Ig/sirolimus. Importantly, FR104/sirolimus did not lead to a beneficial impact on Treg reconstitution or homeostasis, consistent with control of conventional T cell activation and IL-2 production needed to support Tregs. While FR104/sirolimus had a salutary effect on GVHD-free survival, overall survival was not improved, due to death in the absence of GVHD in several FR104/sirolimus recipients in the setting of sepsis and a paralyzed INF-γ response. These results therefore suggest that effectively deploying CD28 in the clinic will require close scrutiny of both the benefits and risks of extensively abrogating conventional T cell activation after transplant.
Benjamin K. Watkins, Victor Tkachev, Scott N. Furlan, Daniel J. Hunt, Kayla Betz, Alison Yu, Melanie Brown, Nicolas Poirier, Hengqi Betty Zheng, Agne Taraseviciute, Lucrezia Colonna, Caroline Mary, Gilles Blancho, Jean-Paul Soulillou, Angela Panoskaltsis-Mortari, Prachi Sharma, Anapatricia Garcia, Elizabeth Strobert, Kelly Hamby, Aneesah Garrett, Taylor Deane, Bruce R. Blazar, Bernard Vanhove, Leslie S. Kean
Title and authors | Publication | Year |
---|---|---|
Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease
Omdahl KI, Bermea RS, Fleming R, Kimler K, Kaminski J, Hariri LP, Ly A, Rui X, Cagnin L, Lane J, Gerdemann U, Blazar BR, Tkachev V, Kean LS |
Science translational medicine | 2025 |
Major breakthroughs in hematopoietic stem cell transplantation and future challenges in clinical implementation
Leslie S. Kean and Bruce R. Blazar |
Journal of Clinical Investigation | 2024 |
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
Neidemire-Colley L, Khanal S, Braunreiter KM, Gao Y, Kumar R, Snyder KJ, Weber MA, Surana S, Toirov O, Karunasiri M, Duszynski ME, Chi M, Malik P, Kalyan S, Chan WK, Naeimi Kararoudi M, Choe HK, Garzon R, Ranganathan P |
Blood Advances | 2024 |
CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD
Verma K, Croft W, Margielewska-Davies S, Pearce H, Stephens C, Diaconescu D, Bevington S, Craddock C, Amel-Kashipaz R, Zuo J, Kinsella FA, Moss P |
Blood Advances | 2024 |
Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation
Kean LS, Burns LJ, Kou TD, Kapikian R, Lozenski K, Langston A, Horan JT, Watkins B, Qayed M, Bratrude B, Betz K, Tang XY, Zhang MJ, Connolly SE, Polinsky M, Gavin B, Gomez-Caminero A, Pasquini MC |
Blood | 2024 |
Lkb1 loss in regulatory T cells leads to dysregulation of hematopoietic stem cell expansion and differentiation in bone marrow
Chen J, Liu J, Huang H |
FEBS Open Bio | 2023 |
Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future
Pan M, Zhao H, Jin R, Leung PS, Shuai Z |
Frontiers in immunology | 2023 |
Facing challenges with hope: universal immune cells for hematologic malignancies
Wang Y, Huang R, Wang Z, Xiong J, Wang X, Zhang X |
Cancer biology & medicine | 2023 |
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.
Buxbaum NP, Socié G, Hill GR, MacDonald KPA, Tkachev V, Teshima T, Lee SJ, Ritz J, Sarantopoulos S, Luznik L, Zeng D, Paczesny S, Martin PJ, Pavletic SZ, Schultz KR, Blazar BR |
Blood Advances | 2023 |
Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates.
Tkachev V, Vanderbeck A, Perkey E, Furlan SN, McGuckin C, Gómez Atria D, Gerdemann U, Rui X, Lane J, Hunt DJ, Zheng H, Colonna L, Hoffman M, Yu A, Outen R, Kelly S, Allman A, Koch U, Radtke F, Ludewig B, Burbach B, Shimizu Y, Panoskaltsis-Mortari A, Chen G, Carpenter SM, Harari O, Kuhnert F, Thurston G, Blazar BR, Kean LS, Maillard I |
Science Translational Medicine | 2023 |
Fibroblastic reticular cells mitigate acute graft-versus-host disease via MHCII-dependent maintenance of regulatory T cells
Haroon Shaikh, Joern Pezoldt, Zeinab Mokhtari, Juan Gamboa Vargas, Duc-Dung Le, Josefina Peña Mosca, Estibaliz Arellano-Viera, Michael AG Kern, Caroline Graf, Niklas Beyersdorf, Manfred B. Lutz, Angela Riedel, Maike Büttner-Herold, Alma Zernecke, Hermann Einsele, Antoine-Emmanuel Saliba, Burkhard Ludewig, Jochen Huehn, Andreas Beilhack |
JCI Insight | 2022 |
Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model
Q Song, U Nasri, D Zeng |
Frontiers in immunology | 2022 |
Identification and Tracking of Alloreactive T Cell Clones in Rhesus Macaques Through the RM-scTCR-Seq Platform
U Gerdemann, R Fleming, J Kaminski, C McGuckin, X Rui, J Lane, P Keskula, L Cagnin, A Shalek, V Tkachev, L Kean |
Frontiers in immunology | 2022 |
Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity.
Wang CJ, Petersone L, Edner NM, Heuts F, Ovcinnikovs V, Ntavli E, Kogimtzis A, Fabri A, Elfaki Y, Houghton LP, Hosse RJ, Schubert DA, Frei AP, Ross EM, Walker LSK |
Nature Communications | 2022 |
Milestones in acute GVHD pathophysiology
Socie G, Michonneau D |
Frontiers in immunology | 2022 |
Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease
Gérard Socié, Leslie S. Kean, Robert Zeiser, Bruce Blazar |
Journal of Clinical Investigation | 2021 |
The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models
T Teshima, GR Hill |
Frontiers in immunology | 2021 |
Current Concepts and Advances in Graft-Versus-Host Disease Immunology
GR Hill, BC Betts, V Tkachev, LS Kean, BR Blazar |
Annual Review of Immunology | 2021 |
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
LT Khuat, M Dave, WJ Murphy |
Gut microbes | 2021 |
GVHD Prophylaxis 2020
M Gooptu, JH Antin |
Frontiers in immunology | 2021 |
Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model
PM Schroder, R Schmitz, ZW Fitch, B Ezekian, J Yoon, AY Choi, M Manook, A Barbas, F Leopardi, M Song, AB Farris, B Collins, J Kwun, SJ Knechtle |
Kidney International | 2021 |
Targeting co-stimulatory molecules in autoimmune disease
NM Edner, G Carlesso, JS Rush, LS Walker |
Nature Reviews Drug Discovery | 2020 |
How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation
B Vandenhove, L Canti, H Schoemans, Y Beguin, F Baron, C Graux, T Kerre, S Servais |
Frontiers in immunology | 2020 |
Cytokines and costimulation in acute graft-versus-host disease
GR Hill, M Koyama |
Blood | 2020 |
Biomarkers for Allogeneic HCT Outcomes
D Adom, C Rowan, T Adeniyan, J Yang, S Paczesny |
Frontiers in immunology | 2020 |
Translational and clinical advances in acute graft-versus-host disease
M Gooptu, J Koreth |
Haematologica | 2020 |
Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’ biomarker
S Paczesny |
British Journal of Haematology | 2020 |
ICOSL + plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist
D Adom, SR Dillon, J Yang, H Liu, A Ramadan, K Kushekhar, S Hund, A Albright, M Kirksey, T Adeniyan, KE Lewis, L Evans, R Wu, SD Levin, S Mudri, J Yang, E Rickel, M Seaberg, K Henderson, CJ Gudgeon, MF Wolfson, RM Swanson, KM Swiderek, SL Peng, KL Hippen, BR Blazar, S Paczesny |
Science Translational Medicine | 2020 |
Superior inhibition of alloantibody responses with selective CD28 blockade is CTLA‐4 dependent and T follicular helper cell specific
GM Muraglia, S Zeng, ES Crichton, ME Wagener, ML Ford, IR Badell |
American Journal of Transplantation | 2020 |
Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD
MH Parker, D Stone, K Abrams, M Johnson, N Granot, R Storb |
Transplantation | 2020 |
Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease
Alexander Ngwube, Niketa Shah, Kamar Godder, David Jacobsohn, Monica L Hulbert, Shalini Shenoy |
Blood Advances | 2020 |
Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease
G Thangavelu, BR Blazar |
Frontiers in immunology | 2019 |
High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune Suppression
CM Castro-Rojas, RR Alloway, ES Woodle, DA Hildeman |
Current Transplantation Reports | 2019 |
Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin
C Orlik, D Deibel, J Küblbeck, E Balta, S Ganskih, J Habicht, B Niesler, J Schröder-Braunstein, K Schäkel, G Wabnitz, Y Samstag |
Cellular and Molecular Immunology | 2019 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |